Information Provided By: 
Fly News Breaks for June 15, 2016
LLY
Jun 15, 2016 | 07:38 EDT
After Eli Lilly's Jardiance EMPA-REG showed a 39% reduction in the risk of kidney disease onset/progression and data for the company's Trulicity diabetes treatment was also favorable, according to SunTrust, the firm says that Eli Lilly's diabetes franchise is "well-positioned for growth." The firm says the data should ease concerns about the company's ability to "more than double its diabetes franchise sales." SunTrust keeps a Buy rating on Eli Lilly.
News For LLY From the Last 2 Days
There are no results for your query LLY
